Pfizer can't derail Celebrex suit; New edict from India; Teva, Lonza rethink biosimilars pact;

 @FiercePharma: Reports of serious reactions to Affymax's Omontys surfaced last August, WSJ says, 6 months b/f recall. More | Follow @FiercePharma

 @EricPFierce: Pfizer's Xeljanzi forecast to hit $1.86 billion by 2016 but Amarin's Vascepa disappoints. Story | Follow @EricPFierce

> Lonza and Teva Pharmaceutical Industries ($TEVA), which suspended their work in October on a biosimilar of Roche's ($RHHBY) drug MabThera, are evaluating whether to proceed with their biosimilar joint venture. Story

> Pfizer ($PFE) was unable to derail a shareholder lawsuit that claims execs made misleading statements about the safety of sales potential of arthritis drugs Celebrex and Bextra. Story

> Teva has gotten FDA approval for Quartette, a new birth control drug developed to minimize breakthrough bleeding between periods. Item

> Canada's Apotex, already in a NAFTA fight with U.S. over a 2009 FDA import ban, has found itself back in the agency's doghouse. Story

> Ranbaxy Laboratories has restored supplies of generic Lipitor in the U.S. Report

Medical Device News

 @FierceMedDev: Dx approach offers chance to spot pancreatic cancer earlier. Story | Follow @FierceMedDev

 @MarkHFierce: Sony and Olympus have delayed their joint medical device venture again. Talk about unrealized potential. More | Follow @MarkHFierce

 @DamianFierce: A Chinese court is asking the SFDA to crack down on local clinical trial regulations. Article | Follow @DamianFierce

> ResMed battles Taiwanese outfit in apnea device patent fight. Item

> Olympus, Sony postpone joint medical device venture indefinitely. Article

> Covidien defeats J&J/Ethicon in surgical tool patent battle. News

Biotech News

 @FierceBiotech: Sanofi to build $75m plant in Vietnam. Market there growing fast, and so is payer coverage. Article | Follow @FierceBiotech

 @JohnCFierce: While India's SC strikes at pharma, the U.K. tees up a sweet tax deal for patented pharma products--the "patent box." More | Follow @JohnCFierce

 @RyanMFierce: Amgen claimed Big Data software prize in $415M deCODE buyout. Report | Follow @RyanMFierce

> New math on biosimilars sends a chilling message to Lonza/Teva team. More

> Clashing stands of India, U.K. on drug patents, R&D will offer clear lessons. Article

> J&J wins first FDA approval for new class of diabetes drug. News

CRO News

> Biotrial takes tech, talent from failing Forenap. Story

> ReSearch launches joint venture with Japanese CRO. News

> bioRASI buys Ukraine CRO for E. Europe heft. Article

> Frontage gets FDA chiding over Chinese lab. Item

> Chinese court wants tougher clinical trial regs. Report

Biotech IT News

> George Church-affiliated startup blueprints genetic data marketplace. News

> FoldIt creator wins Bill Gates nod for science crowdfunding site. Item

> Sequoia-backed genomics startup, others face who-pays hurdle. Story

> NSF touts role of supercomputer in autism, neuroscience discoveries. Article

> Big Data sheds light on pharma's 'Small Data' problems. Industry Voices

> 5 keys to going mobile in pharma. Editor's Corner

And Finally... India, which has significantly increased the number of drugs covered by price controls, says manufacturers must give a 6-month notice if they are discontinuing a product and that the government can force them to continue production to meet essential needs. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.